Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
HanAll Biopharma Co Ltd (HanAll) biopharmaceutical company that develops innovative medicines for patients. The company pipeline products include HL192 for parkinson’s disease; HL036 which treats dry eye disease; HL161ANS targets autoimmune disease; HL161 for the treatment of myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy and graves’ disease; HL187 and HL186 treat cancer. It partners with global pharmaceutical companies and academic institutions. The company operates in the US, Japan, Korea and Indonesia. HanAll is headquartered in Seoul, South Korea
Headquarters
South Korea
Address
43, Sangseodang 1-Gil, Daedeok-Gu, Daejeon, Seoul, 34344
Website
www.hanall.co.kr
Telephone
82 42 9325997
No of Employees
315
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
009420 (KRX)
Revenue (2024)
$109.2M
11.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-208%
(2024 vs 2023)
Market Cap*
$2.1B
Net Profit Margin (2024)
XYZ
-175.4%
(2024 vs 2023)
* As of and is in US$
HanAll Biopharma Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Neurology: |
| HL192: Parkinson's Disease (PD) |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | HanAll Biopharma Co Ltd | Daewoong Pharmaceutical Co Ltd | Huons Global Co Ltd | DAE HWA Pharmaceutical Co Ltd | Ilsung IS Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Daejeon | Hwaseong | Seongnam | Hoengseong | Seoul |
| State/Province | Seoul | - | - | - | - |
| No. of Employees | 315 | 1,749 | 541 | 424 | 194 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jae Chun Yoon | Chairman | Executive Board | 2015 | - |
| Seung-kook Park, Ph.D. | Vice Chairman | Executive Board | 2013 | - |
| Sean Jeong, M.D. | Co-Chief Executive Officer; Director | Executive Board | 2021 | - |
| Su-jin Park | Director; Co- Chief Executive Officer | Executive Board | 2023 | - |
| Hyeakyung Ahn | Head - Bio Research Center | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer